Thank you.
You'd be aware, of course, that the drug safety and effectiveness network reported back that, in fact, there's a strong association.
On CIHR, or Canadian Institutes of Health Research, I see you've made a remarkable transformation here. The money used to be almost all dedicated to investigator-initiated health research. But I see your second is priority-driven health research.
On the same issue, we have a promising, but not established yet, use of probiotics as a preventative measure, not as a treatment measure, for C. difficile. But the study done, right out of a hospital here, nine years experience in Montreal as a lead agency, had 95% reduction in C. difficile. It hasn't been confirmed with other studies, because many use underpowered probiotics. This is nearly 100 billion CFUs administered through Bio-K Plus.
Would that be a possibility as a priority-driven health research, which is designed, as I see, targeted research to address challenges facing Canadians, where we might be able to engage CIHR to take some of our worst hospitals where there's a high incidence of C. difficile and actually check out the preventative measures—36 hours after starting antibiotics, they get a probiotic—and eliminate a high percentage of these infections?